ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements
Archit Organosys approved unaudited results for the quarter and half year ended September 30, 2026. The auditor's limited review report is attached.
Archit Organosys will hold a board meeting on November 4, 2026 to consider unaudited results for the quarter and half year ended September 30, 2026. The trading window has been closed since October 1, 2026.
A standard quarterly shareholding pattern filing submitted by Archit Organosys Ltd as per SEBI Regulation 31(1)(b) requirements.
Archit Organosys Limited submitted the voting results of its 33rd Annual General Meeting held on September 30, 2026. All resolutions were passed by the shareholders.
Archit Organosys Limited issued a corrigendum to its FY 2025-26 Annual Report, withdrawing Agenda Items 8, 9, and 10 from the upcoming AGM notice.
Archit Organosys has withdrawn three agenda items from the upcoming AGM, including an authorised capital increase, an acquisition, and a proposed preferential issue for restructuring.
Archit Organosys Limited announced its 33rd Annual General Meeting to be held on 30th September 2026. The board recommended a dividend of Re. 1 per share.
Archit Organosys Ltd has filed its Annual Report for the financial year 2025-26. The submission includes audited financial statements and director's reports for the period.
Archit Organosys has fixed September 23, 2026, as the record date to determine shareholder eligibility for the final dividend recommended for FY 2025-26.
Archit Organosys will issue 3.72 crore shares via preferential allotment at ₹65/share, totaling ₹242.11 Crore, to acquire a stake in Archit Life Science Limited.
Archit Organosys Ltd announced a board meeting on September 3, 2026, to evaluate proposals for raising funds through the issuance of equity shares or other securities.
Archit Organosys Ltd reported revenue from operations of ₹37.1 Cr (+11.7% YoY) and net profit of ₹1.4 Cr (-30.0% YoY) for Q1 FY27.
Archit Organosys has scheduled a Board Meeting on August 12, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Archit Organosys Ltd reported revenue from operations of ₹36.5 Cr (-15.5% YoY) and net profit of ₹2 Cr (+0.0% YoY) for Q4 FY26.
Archit Organosys approved audited financial results for fiscal year 2026, reporting a profit of ₹8.05 Crore. The board also recommended a ₹1 per share final dividend for investors.
Archit Organosys scheduled a board meeting on May 16, 2026, to approve audited annual results and dividend. The trading window remains closed for designated persons.
Archit Organosys Limited scheduled a board meeting for May 16, 2026, to approve annual financial results. The trading window remains closed until 48 hours post-announcement.
Archit Organosys Ltd clarified to BSE that recent share price movements are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or impending corporate actions. It remains in compliance with SEBI LODR regulations regarding all necessary disclosures.